Network meta-analysis of 16 RCTs (10,266 patients) in scalp psoriasis: all biologics and small molecules beat placebo for scalp clearance, with ixekizumab Q2W (OR 54.02) and brodalumab (OR 53.16) ranked highest; apremilast alone raised AE discontinuation.
Meta-analysisn = 10,266
Lai et al. Systematic review and network meta-analysis of biologics and small molecules for scalp psoriasis